Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-05
2011-04-05
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S155100, C424S156100, C424S178100, C424S183100
Reexamination Certificate
active
07919087
ABSTRACT:
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5846534 (1998-12-01), Waldmann et al.
patent: 6653104 (2003-11-01), Goldenberg
patent: 2002/0018749 (2002-02-01), Hudson et al.
patent: 98/50435 (1998-11-01), None
patent: 00/67795 (2000-11-01), None
patent: 00/74718 (2002-12-01), None
Tutt et al, 1998, J Immunology, 161(6): 3176-85.
Gondo et al, 1987, British J Haemotology, 67(4): 413-7.
Banapour B et al, 1987 (J Immunol, 139 (12): 4027-4033.
Perezsoler et al, 1995, ACS symposium series, 574: 300-319.
Zhengxing Qu et al. “Internalization and Cytotoxic Effects of a Humanized Anti-CD74 Antibody, LL1,” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NH, vol. 43, (2002), p. 255, XP001153818.
Ochakovskaya et al., Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with 111Indium, 67Gallium, or 90Yttriuml, Clinical Cancer Research, U.S. vol. 7, No. 6, (2001) pp. 1505-1510, XP002255675.
P. Moller et al., “CD74,” Journal of Biological Regulators and Homeostatic Agents (2001), Italy, vol. 14, No. 4, (2000), pp. 299-301, XP009018091.
Shih et al., “Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice” Cancer Immunol Immunother (2000), 49:208-216.
Ibragimova, et al., “Stability of the Beta-Sheet of the WW Domain: A Molecular Dynamics Simulation Study,” Biophysical Journal, Oct. 1999 vol. 77, pp. 2191-2198.
Hansen et al., “Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by Beta-cell-lymphomas,” Biochem J. (1996), 320:293-300.
Bendig, Mary M. “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,” Academic Press Inc., New York, NY, vol. 8 (1995), pp. 83-93, XP002943667.
Colman et al., “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology (1994), 145:33-36.
Oster, Wolfgang, et al., “Erythropoietin for the Treatment of Anemia of Malignancy Associated with Neoplastic Bone Marrow Infiltration” Journal of Clinical Oncology, vol. 8, No. 6, Jun. 1990 pp. 956-962.
Burgess et al., Journal of Cell Biology, vol. 111, Nov. 1990, pp. 2129-2138.
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. National Academy Science USA, 86:3833-3837 (1989).
Lazar, et al., “Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, Mar. 1988, vol. 8, No. 3, pp. 1247-1252.
Kolata, G., et al., “Clinical promise with new hormones” Science 236, 517 (1987); DOI: 10:1126/Science 3495036.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. National Academy Science USA (1982) vol. 79, p. 1979.
Goldenberg David M.
Hansen Hans J.
Leung Shui-on
Qu Zhengxing
Huff Sheela J
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Internalizing anti-CD74 antibodies and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Internalizing anti-CD74 antibodies and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Internalizing anti-CD74 antibodies and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699717